HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:
Health OTC Drugs Business Strategies

David Vs Goliath – Flarin’s Macmillen On Slugging It Out With The Heavyweights

  • Interviews

Executive Summary

HBW Insight Exclusive: Flarin boss Andrew Macmillen on competing with the big OTC incumbents as a lean, innovation-focused company.

You may also be interested in...



P&G JV Clearblue Empowers British Women Trying To Conceive

Procter & Gamble joint venture Clearblue has launched a UK PR campaign aimed at de-stigmatizing the conception pre-pregnancy phase by putting control and confidence back in women’s hands.

Asia’s OTC Market Stunted By Regulatory Disharmony

HBW Insight Exclusive: A lack of regulatory harmonization, especially with regards to Rx-to-OTC switch, is holding the Asia-Pacific OTC market back, according to APSMI secretary general, Toshi Tominaga.

German OTC Marketing Round-Up: Allergy Launches From Novartis, Hevert, Dermapharm And Bencard

OTC marketing news from Germany: A hard-won desloratadine launch from Novartis, two new products from Dermapharm, as well as homeopathic and probiotic alternatives from Hevert and Bencard. 

Table

View full table

Topics

Tags:
Health OTC Drugs Business Strategies
UsernamePublicRestriction

Register

WI964834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By